Evaluation of quaternized and neutral muscarinic receptor ligands in normal and DES-treated rat by Otto, Charlotte A. et al.
Nucl. Med. Rio/. Vol. 18, No. 5, pp. 557-561, 1991 
Inl. J. Radial. ApI. Instrum. Parr B 
Printed in Great Britain. All rights reserved 
0883-2897/91 $3.00 + 0.00 
Copyright 0 1991 Pergamon Press plc 
Evaluation of Quaternized and 
Neutral Muscarinic Receptor Ligands in 
Normal and DES-treated Rat 
C. A. OTTO’, G. K. MULHOLLAND2, S. B. DEMATTOS’, 
P. S. SHERMAN’, T. L. PISAN12 and G. HINGORANI’ 
‘The University of Michigan-Dearborn, Dearborn, MI 48128 and ZThe Division of Nuclear Medicine, 
University of Michigan Medical Center, Ann Arbor, MI 48109, U.S.A. 
(Received 29 March 1990; for publication 21 September 1990) 
The localization of quaternized muscarinic receptor (mAChR) antagonists, [“C]methyl tropanyl benzilate 
([“CIMTRB) and [“Clmethyl quinuclidinyl benzilate ([“CIMQNB), in rat pituitary was compared to that 
of [“Cltropanyl benzilate ([“CJTRB), a neutral antagonist. The quatemized ligands localize via a 
mAChR-mediated mechanism as shown by 60% reduction in radioactivity concentrations in the presence 
of QNB. [“CITRB appears to localize primarily by a non-mAChR specific mechanism. Induction of 
pituitary prolactinomas by diethylstilbestrol resulted in a reduction of [“C]MTRB pituitary localization 
compared to normals. Elevated serum prolactin levels due to prolactinoma presence had no measurable 
effect on myocardial [“CIMTRB uptake or on I$ values. i?,, values for myocardial mAChR were similar 
for controls and for DES exposure of 10 weeks. 
Muscarinic receptors (mAChRs) are intrinsic mem- 
brane proteins found in many tissues which elicit an 
array of biochemical responses from control of heart 
rate to neurotransmission in the brain. Imaging these 
receptors could yield medically useful data from both 
the central nervous system and peripheral organs 
such as the heart. Rather than synthesizing a large 
number of potential ligands in radioactive form, we 
developed a two stage assay system to preselect target 
hgands. The first stage consisted of a competitive 
in vitro binding assay designed to provide information 
on relative binding affinities. The second stage was an 
ex viva assay which provided information on both 
in oiuo distribution and kinetics (Otto et al., 1989). 
Application of this screening procedure lead to radio- 
synthesis and further studies of the following ligands: 
[“Cl-( +)-2a-tropanyl benzilate ([“C]TRB) and [“CJ- 
N-methyl piperidyl benzilate ([“CINMPB) (Mulhol- 
land et al., 1988a,b, 1989) (see Fig. 1). Our initial 
objective in synthesizing [“CIMTRB was to check 
its feasibility as a myocardial imaging agent. Gibson 
et d. (1979) demonstrated that quatemization 
of t3H]QNB to form t3H]MQNB lead to better 
heart/lung ratios than observed with rH]QNB. Other 
investigators, using [“CIMQNB, verified that the 
complications of non-specific lung uptake of neutral 
mAChR ligands were reduced with quaternization 
(Maziere et al., 1981; Syrota et al., 1985). 
In studying [“CIMTRB in viva, we noted a differ- 
ence in behavior between [“CITRB and [“CIMTRB 
in the pituitary. Pituitary localization of both ligands 
was expected as mAChRs have been described in the 
pituitary (Avissar et al., 1981; Shaeffer and Hsueh, 
1980; Burt and Taylor, 1980; Mukherjee et al., 1980). 
The in oivo demonstration of mAChR-mediated 
pituitary localization of [3H]NMPB (Avissar et al., 
1981) together with the difference in behavior of the 
tropanyl benzilate ligands prompted a more thorough 
evaluation of “C labeled muscarinic antagonists in 
the pituitary. 
Having an interest in detecting the presence of 
pituitary prolactin secreting adenomas (prolactin- 
omas), we evaluated both [“C]TRB and [“CIMTRB 
in a rat model for prolactinoma. Diethylstilbestrol 
(DES) implanted in the F344 rat lead to increased 
serum prolactin levels (Wiklund et al., 1981). Further 
characterization of this model verified the increases 
in serum prolactin levels and pituitary weight, and 
documented increases in percent prolactin secreting 
cells (Otto et al., 1986a). Although the role of the 
mAChR receptor in the pituitary has yet to be 
sharply defined, there is evidence for cholinergic 
control of prolactin secretion (Carmeliet and Denef, 
1988; Hall et al., 1984; Sharif, 1988). Comparison of 
mAChR antagonist localization in normal rat pitu- 
itary with localization in a prolactinoma model might 
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reveal differences in mAChR density that would aid 
in understanding the role of cholinergic influence in 
the pituitary. 
Our efforts were directed towards (1) comparing 
uptake of both neutral and quaternized mAChR 
radioligands in pituitary tissue, heart and brain, 
(2) evaluating the effects of DES-treatment on radio- 
labeled mAChR ligand uptake in pituitary, heart and 
brain and (3) determining the effects of high circulat- 
ing prolactin levels on the biochemical characteristics 
(&,a, and Ko) of myocardial mAChR. 
Materials and Methods 
Drugs 
Non-radioactive precursor (+)-2x-tropanyl benz- 
ilate (TRB) was prepared by base catalyzed trans- 
esterification of (+)-2a-tropanol with methyl benzilate 
(Atkinson etal., 1977). N-Desmethyl-( +)-2a-tropanyl 
benzilate (nor-TRB) and (+)-2a-tropanol were kindly 
provided by Dr Edward R. Atkinson. N-Methyl- 
4-piperidyl benzilate and 4-piperidyl benzilate were 
synthesized by literature procedures (Biel et al., 1961). 
(-)-Quinuclidinyl benzilate was purchased from 
Research Biochemicals Inc., Natick, Mass., U.S.A. 
Carbon-l 1 syntheses of [“CITRB, [“C]MTRB 
(Mulholland et al., 1989), [“C]NMPB (Mulholland 
et al., 1988a,b) and [“CIMQNB (Syrota et al., 1985) 
were conducted by reacting the appropriate precursor 
(l-2 mg in 200 p L of N,N-dimethyl formamide) with 
high specific activity [“Clmethyl iodide and then 
isolating products by normal phase chromatography. 
The radiochemical purities and specific activities of 
final formulated products were determined by ana- 
lytical reversed phase HPLC (4.6 x 250 mm C-18 5~ 
3: 1: 1 acetonitrile:methanol:20 mM KHPOI, pH 6.7, 
1 mL/min, U.V. (220 nm)/radioactivity (NaI), lower 
detection limits: lo-30 ng. Specific activities at the 
end of synthesis were in the range of 300-4000 Ci/ 
mmol and the radiochemical purities were greater 
than 98%. 
The following compounds were obtained from 
commercial sources: [3H]-N-methyl scopolamine 
([3H]NMS) (35-70 Ci/mmol) (New England Nuclear), 
diethylstilbestrol (DES) (Aldrich Chemical Company), 
atropine sulfate (Sigma), scintillation cocktail (ICN 
Biomedical). Fischer F344 and Sprague-Dawley 
female rats were purchased (Harlan). Animals were 
exposed to alternating 12 h periods of light and dark 
and received rat chow and water ad libitum during the 
study. 
Tissue distribution studies 
Tissue distribution studies were performed in both 
F344 female rats weighing between 170 and 225 g at 
5, 15, 45, 60 and 90 min post injection and in female 
Sprague-Dawley rats weighing between 150 and 
250 g. DES-treated rats were implanted as previously 
described (Otto et al., 1986) and used in tissue 
distribution studies at O-16 weeks post implant. 
Radiolabeled drugs (50-200 PCi in less than 250 p L 
total volume) were administered intravenously (ex- 
cept where noted) in the femoral vein to rats anes- 
thetized with ether. Animals (N = 3 per time interval) 
were anesthetized and killed by decapitation. The 
brains and other tissues were removed rapidly, 
counted for carbon-l 1 and then weighed. Tissue 
concentrations were calculated in terms of percent 
injected dose per gram (%ID/g) or percent injected 
dose per organ (%ID/organ). For QNB blocking 
studies, rats (N = 3) were pretreated intraperitoneally 
(i.p.) with fQNB (2 or 6.6mg/kg body weight 
depending on study) either 10min or 1 h prior to 
radiodrug injection. Control rats (N = 3) were pre- 
treated with saline vehicle only. 
In vitro ussny jar heart rissue 
Hearts from DES-treated rats were excised at 10 
and 16 weeks post DES implant and stored at -80°C 
until used. Hearts from non-DES-treated rats were 
collected and frozen until used. For the assay, hearts 
were thawed and homogenized in ice-cold 50 mM 
Na-K phosphate buffer (pH 7.4) (hereafter referred 
to as buffer); about 0.6 g tissue were homogenized in 
11.5 mL buffer. Protein concentration was determined 
using the Bradford assay (Bradford, 1976) (standard: 
bovine serum albumin). Protein concentration of the 
homogenate was 0.24-0.28 mg/assay volume. To assay 
the binding of [jH]NMS, triplicate samples of 50 ,nL 
of homogenate in buffer containing a minimum of 10 
different concentrations of [3H]NMS were used. Non- 
specific binding was also determined in triplicate by 
including 1 PM atropine sulfate in the assay. Each 
assay was initiated by addition of homogenate to 
yield a final volume of 1.2 mL and incubated at room 
temperature for 2 h. The assay was terminated by 
addition of 3.0 mL of ice-cold buffer followed by 
immediate vacuum filtration using glass fiber filters 
(Schleicher & Schuell No. 32) presoaked in 2.5% 
polyethylenimine. After washing the filters with 
3 x 3.0 mL cold buffer, they were transferred to a 
scintillation vial. Cocktail was added and the vials 
stored in the dark for 12 h before counting (64% 
efficiency). The count data was analyzed using the 
LUNDON-1: Saturation Analysis: Radioligand 
Binding curve analysis package (Lundon Software 
Inc., Cleveland, Ohio). 
Results and Discussion 
Rat biodistribution studies were performed at 
t = 30 min (see Table 1). The expected differences in 
brain penetration of quaternized ([“CIMTRB and 
[“CIMQNB) and neutral ([“CITRB) mAChR ligands 
was observed: the neutral ligand has a 300-fold higher 
concentration in brain than the quatemized (positively 
charged) ligands. However, both neutral and qua- 
tern&d radioligands had comparable pituitary 
uptake at 30min. Heart uptake was higher for 
[“CIMTRB than for either [“CIMQNB or [“C]TRB 
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Table I. Comparison of [“CIMTRB, [“CJMQNB and (“CJTRB 
in various rat* tissues at I = 30 min; data as %ID/g + SEM 
Tissue l”C]MTRBt [“CJMQNBt [“C]TRB$ 
Brain 0.009 * 0.001 0.010 + 0.000 2.95 + 0.17 
Pituitary 1.03 kO.12 0.841 kO.138 1.58 i 0.19 
Heart Il.75 + 0.91 7.71 * 1.54 4.95+0.11 
Blood 0.032 + 0.005 0.035 * 0.014 0.1 I1 * 0.027 
a001 
MQNB MTRB TRB 
*Fischer F344 female rats. tN = 3. $N = 10. 
(for further discussion of [“CIMTRB in the myo- 
cardium see Mulholland et al., 1988~). 
Blockade by QNB pretreatment of mAChR, at 
t = 30 min, was employed in order to demonstrate 
receptor mediation as the mechanism for tissue local- 
ization. Figure 2 shows the effects of QNB pretreat- 
ment (2.0 mg/kg of +_ QNB 60 mm prior to radiotracer 
administration) on the radioactivity localization in 
heart, pituitary and brain for [“C]TRB, [“CIMTRB 
and [“CIMQNB. QNB clearly reduced the tissue 
concentration of all compounds in the myocardium. 
Unexpectedly, the effects of QNB on pituitary uptake 
of neutral ([“CITRB) and quaternized ([“CIMTRB 
and [“CIMQNB) mAChR ligands were different. 
The uptake of [“C]TRB was reduced by 17% when 
pretreated with QNB (control: 1.59 + 0.19% ID/g; 
QNB: 1.31 +_ 0.09) whereas the concentration of 
[“CIMTRB in the pituitary was reduced by 68% and 
that of [“CIMQNB by 85%. Clearly the localization 
in normal pituitary of [“CIMTRB and [“C]MQNB 
can be significantly reduced by QNB pretreatment 
whereas only a small reduction is observed for 
[“CITRB. 
The pituitary uptake of [“CITRB is similar to that 
reported for [‘HINMPB, a neutral mAChR antagonist 
(Avissar et al., 1981). Using a different protocol for 
QNB pretreatment, the uptake of t3H]NMPB was 
reduced by about 30% in the pituitary. The QNB 
pretreatment protocol of Avissar et al. (1981) was 
followed except for the use of 6.6 mg/kg body weight 
of + QNB in place of 3.3 mg/kg of active QNB. This 
Muscarinic ligands 
tm Heart EZI Hwt + QNB 8 Pituitary 
h9 Pigary + m Brain 0 Brain + ONE 
Fig. 2. Comparison of the effect of QNB on pituitary, heart 
and brain uptake at I = 30 min. Fischer F344 rats were 
injected with vehicle only or with 2.0 mg/kg body weight 
60 min prior to radioligand administration. Data are the 
average of N = 3 for [“CIMQNB and [“CIMTRB; N = IO 
for [“CITRB. 
protocol resulted in a reduction of [“C]TRB localiz- 
ation in brain and heart by > 79% but a reduction in 
the pituitary of less than 36%. These results again 
demonstrate the inability of QNB to reduce pituitary 
localization of [“CITRB to the extent observed 
in other tissues containing mAChR receptors. We 
conclude that neutral mAChR antagonists behave 
differently in the pituitary than the quaternized 
antagonists. It is possible that the localization of 
13H]NMPB and [“CITRB in the pituitary is a combi- 
nation of a non-mAChR specific uptake mechanism 
and a receptor-mediated mechanism with non- 
mAChR uptake predominating. Differences in uptake 
between neutral and quaternized antagonists have 
been reported in the lung (Gibson et al., 1979). Similar 
results, i.e. largely non-receptor-mediated localization, 
were reported for the pituitary uptake of rH]- 
spiroperidol, a dopaminergic D, antagonist (Otto 
et al., 1986b). Spiroperidol is similar to TRB and 
NMPB in that all are neutral amines. These results 
[ “CINMPB 
Fig. 1. Structures of mAChR antagonists. [“CITRB and [“CINMPB are neutral ligands; [“CIMTRB and 
[“CIMQNB are quaternized. 
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Fig. 3. Time course of radioactivity concentration of 
[“C]TRB, [“CjMTRB and [“CINMPB in pituitary tissue of 
Sprague-Dawley rats. Data as %ID/g + SEM; N = 3 for 
each data point. 
suggest that a general mechanism for uptake of 
neutral amines operates in the pituitary. 
We also compared the time course of [“CIMTRB, 
[“CjTRB and [“CINMPB in the pituitary of Sprague- 
Dawley rats (see Fig. 3). [“C]TRB has higher pitu- 
itary localization values than either [“CINMPB or 
[“CIMTRB. Despite the differences in effects of QNB 
pretreatment (about 30% for [)H]NMPB and 68% 
for [“CIMTRB), the radioactivity concentration of 
both ligands is similar at each time point. 
To study the effect of DES exposure, the time 
course of [“CIMTRB in rats exposed to DES for 10 
weeks, the effects of QNB pretreatment and the effects 
of differing lengths of exposure to DES on [“CjMTRB 
localization were determined. In contrast to the time 
course of [“CIMTRB in Fischer F344 rats (1.49 + 
0.31 %ID/g at t = 2 min to 1.71 +- 0.42 at t = 60 min), 
the time course in DES-implanted animals showed a 
steadily decreasing %ID/g tumor over the same time 
frame (0.392 + 0.037 to 0.134 + 0.002). Receptor- 
mediated localization was demonstrated as above. 
QNB pretreatment of rats exposed to DES for 6 
weeks reduced [“C]MTRB tumor localization by 77% 
(%ID/g for controls was 0.442 + 0.107; for QNB 
treated rats, 0.100 + 0.025). As the length of exposure 
increases from 0 to 15 weeks, the %ID/organ of 
[“CIMTRB increases from 0.009 f 0.002 for controls 
to 0.209 f 0.008 at 15 weeks of DES, a 23-fold 
increase. However, when corrected for increasing 
tumor weight the %ID/g tumor decreased from 1.03 
f 0.12 (control rats) to 1.28 + 0.22 at 6 weeks DES 
to 0.830 f O.OOg at 15 weeks DES. 
Histological characterization of the DES-induced 
tumors after 4 weeks of DES exposure in female F344 
rats showed (1) that the percent of prolactin (PRL) 
secreting cells increased from 32.3 + 1.4% to 79.7 
_+ 1.0, a 2.5-fold increase, and (2) that there was a 
5-fold increase in serum PRL levels (Otto et al., 
1986a). Since the %ID/g tumor decreases while the 
percent of PRL secreting cells increases, it appears 
that there may be changes in either B,,, or K,, relative 
to normals. It is not clear whether these results are 
due to DES or to high circulating levels of prolactin. 
The presence of estrogen affected in vitro agonist 
binding to mAChR by reducing the proportion of high 
affinity binding sites and by decreasing the dissociation 
constant (Sokolovsky et af., 1981). If estrogen effects 
occur in vivo, the changes in localization of [“Cl- 
MTRB, albeit an antagonist instead of an agonist, 
may be related to DES presence. Efforts are under- 
way to determine these binding characteristics in 
DES-treated pituitary tissue. 
The heart uptake of [“CIMTRB appears to be 
constant from 6 to 15 weeks of exposure to DES, 
suggesting that minimal change in myocardial 
mAChR density or in kinetic behavior results from 
high circulating PRL levels (Otto et af., 1986a). 
Competitive binding assays using hearts from the DES 
treated rats at 10 and 16 weeks post implant were 
compared to data from normal hearts. [‘H]NMS 
(Brown and Goldstein, 1986; Aguilar and De Robertis, 
1987) was employed as radioligand in this assay as it 
is a quaternized ligand and thus similar to [“Cl- 
MTRB. In each case, analysis of binding data using 
LUNDON- 1 was performed. Comparison of a model 
for one site with a model for one site plus non- 
saturable binding (the next most complex binding 
model), yielded F test scores of co.01 and runs test 
scores of >0.05. Both scores support the one site 
model as the best fit for the data (Lundeen and 
Gordon, 1986). A minimum of 14 different ligand 
concentrations were included in each curve analysis. 
Non-linear analyses were used as opposed to 
Scatchard-Rosenthal analysis to determine KD and 
B,,,,, values. Values of KD did not change: for normal 
hearts, KD was 5.8 f 0.3 x lo-” mol; for 10 week 
DES hearts, 4.8 + 0.4 x lo-“; for 16 week DES, 
5.0 _+ 0.25 x lo-“. Values for B,, were similar for 
control hearts (8.6 + 0.4 x lo-l4 mol/mg protein) and 
10 week DES hearts (7.9 + 0.2 x 10-‘4). These data 
are in agreement with a study which showed that 
the density of mAChR, as measured with [3H]QNB, 
was constant in rats implanted with the MtTWl5 
adenoma for 5 weeks (Nelson et al., 1987). B,,,,, values 
in 16 week DES hearts increased to 16 + 2 x lo-“. 
Further study is needed to verify and determine the 
significance of this increase. 
In conclusion, these studies have shown that 
[“CITRB localization in the pituitary is not primarily 
receptor-mediated whereas the localization of the 
quaternized ligands, [“CIMTRB and [“CIMQNB is 
receptor-mediated as demonstrated by reduction of 
radioactivity levels in the presence of QNB. The 
presence of DES-induced prolactinomas decreased 
tissue concentration of [“CIMTRB in the pituitary. 
DES treatment did not affect [“CIMTRB localization 
in the myocardium as evidenced by tissue concen- 
tration values and by similarity in KD and B,,,,, value 
in normal and 10 week DES-treated rat hearts. 
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